Back
Perspective Therapeutics, Inc. 10K Form
Sell
40
CATX
Perspective Therapeutics, Inc.
Last Price:
$2.4000
Seasonality Move:
21.96%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive CATX News And Ratings
See the #1 stock for the next 7 days that we like better than CATX
CATX Financial Statistics
Sales & Book Value
| Annual Sales: | $1.5M |
|---|---|
| Cash Flow: | $-18.3M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $3.26 |
| Price / Book: | 0.73 |
Profitability
| EPS (TTM): | -1.45850 |
|---|---|
| Net Income (TTM): | $-106.3M |
| Gross Margin: | $-852K |
| Return on Equity: | -37.63% |
| Return on Assets: | -31.7% |
Perspective Therapeutics, Inc. Earnings Forecast
Key Perspective Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 31 years for CATX is -58.60%.
-
The Selling, General & Administrative Expenses for CATX have been equal to 1,830.33% of Gross Profit Margin.
-
The Research & Development expenses have been 2,705.09% of Revenue.
-
The Net Earning history of CATX is -5,387.21% of Total Revenues.
-
Per Share Earnings over the last 31 years have been positive in 16 years.
Perspective Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NYAM |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | CATX |
| Website: | perspectivetherapeutics.com |
Debt
| Debt-to-Equity Ratio: | 0.01 |
|---|---|
| Current Ratio: | 8.66 |
| Quick Ratio: | 8.47 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
CATX Technical Analysis vs Fundamental Analysis
Sell
40
Perspective Therapeutics, Inc. (CATX)
is a Sell
Is Perspective Therapeutics, Inc. a Buy or a Sell?
-
Perspective Therapeutics, Inc. stock is rated a SellThe current Perspective Therapeutics, Inc. [CATX] share price is $2.3900. The Score for CATX is 40, which is 20% below its historic median score of 50, and infers higher risk than normal.